Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Apixaban is a potent, oral, selective reversible direct inhibitor of factor Xa with a
favorable efficacy and safety profile in the prevention of non valvular (NV) atrial
fibrillation (AF). It has been shown, including by our group, that D-dimers levels (molecular
marker of coagulation activity) are predictive of the events (including mortality) in patient
with AF independently of the antithrombotic treatment. The aim of the study is to evaluate
the changes in plasma levels of biomarkers of coagulation activation: D-dimers, prothrombin
fragments F1+2, von Willebrand factor (vWF) and thrombin-antithrombin complexes (TAT) in
response to apixaban treatment in patients with NVAF.